Back to top
more

2seventy bio, Inc. (TSVT)

(Delayed Data from NSDQ)

$5.05 USD

5.05
867,843

+0.18 (3.70%)

Updated Sep 20, 2024 03:59 PM ET

After-Market: $5.06 +0.01 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TSVT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for 2seventy bio, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 217 266 265 0 0
Receivables 13 21 17 11 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 7 14 10 14 0
Total Current Assets 238 301 292 25 0
Net Property & Equipment 58 56 35 144 0
Investments & Advances 5 1 97 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 7 19 22 19 0
Deposits & Other Assets 38 38 39 8 0
Total Assets 565 657 760 313 0
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 6 7 6 7 0
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 26 55 55 43 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 15 7 27 10 0
Total Current Liabilities 60 80 98 76 0
Mortgages 0 0 0 0 0
Deferred Taxes/Income 4 5 26 26 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 2 3 24 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 310 346 400 238 0
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 767 607 400 0 0
Retained Earnings -511 -294 -39 0 0
Other Equity 0 -3 -1 75 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 255 310 360 75 0
Total Liabilities & Shareholder's Equity 565 657 760 313 0
Total Common Equity 255 310 360 75 0
Shares Outstanding 50.60 37.90 23.50 NA NA
Book Value Per Share 5.05 8.19 15.31 0.00 0.00

Fiscal Year End for 2seventy bio, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 202 181 217 251 283
Receivables 18 12 13 20 44
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 5 19 7 7 7
Total Current Assets 225 213 238 277 334
Net Property & Equipment 37 38 58 61 61
Investments & Advances 0 0 5 34 24
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 6 6 7 7 19
Deposits & Other Assets 40 38 38 38 38
Total Assets 518 511 565 641 706
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 3 9 6 5 6
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 29 22 26 37 36
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 16 15 13 13
Total Current Liabilities 47 60 60 68 67
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 2 4 16 17
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 2 2 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 283 304 310 334 338
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 774 772 767 762 752
Retained Earnings -539 -564 -511 -454 -383
Other Equity 0 0 0 -1 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 235 207 255 306 368
Total Liabilities & Shareholder's Equity 518 511 565 641 706
Total Common Equity 235 207 255 306 368
Shares Outstanding 51.40 51.40 50.60 50.40 50.20
Book Value Per Share 4.57 4.04 5.05 6.08 7.32